Harbour Biomed gives Hong Kong new IPO dose
China's Harbour Biomed, a clinical-stage biopharmaceutical company, has hit the road for its up to HK$1.8bn ($230.4m) listing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts